Background: Large granular lymphocytic leukemia (LGLL) is a chronic lymphoproliferative disorder characterized by the clonal proliferation of large granular lymphocytes (LGL), classified as T and NK subtypes. Although JAK/STAT pathway gene mutation, such as STAT3/STAT5B, is the dominant driver in the proliferation of LGLL, immune abnormality remains an unsolved puzzle in the pathogenesis.

Methods: By means of bioinformatic method through the GEO dataset GSE39838, we performed the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, as well as protein-protein interaction network (PPI) module calculation.

Results: As a consequence, differentially expressed genes (DEGs) involved in immune regulation were detected to be related with LGLL, including C1QA, C1QC and CD163 etc. Among all the DEGs, 147 genes were up-regulated, while the number of down-regulated genes was 1,296. In the KEGG pathway of LGLL, infection and immunity were the primary alteration, including tuberculosis and rheumatoid arthritis (RA). However, meticulous experiments are required to validate.

Conclusions: To sum up, dysimmunity might be another internal anomaly of LGLL, thus it is a reminder that immune regulation of LGLL should be paid more attention. Moreover, immune microenvironment studies in LGLL covering T, B, and NK cells probably contribute to the molecular pathology, aiming to contribute to the molecular pathology of the LGLL. Additionally, pharmaceutical development directed at immune molecules might be pre-dictive of targeted therapy era in LGLL.

Download full-text PDF

Source
http://dx.doi.org/10.7754/Clin.Lab.2020.200819DOI Listing

Publication Analysis

Top Keywords

large granular
12
lgll
10
granular lymphocytic
8
lymphocytic leukemia
8
leukemia lgll
8
immune regulation
8
contribute molecular
8
molecular pathology
8
immune
5
discovery dysimmunity
4

Similar Publications

Article Synopsis
  • Estimates indicate significant variation in R&D costs, with 20 large firms comprising 80.8% of patient-months and showing lower costs per patient-month compared to smaller firms.
  • A novel methodology was used to analyze R&D costs per drug, focusing on discrete units of activity related to clinical trials and using data from 268 US publicly traded drug developers.
  • The study found that R&D costs per new drug averaged around $1.31 billion, with a lower median cost of $708 million, highlighting a skewed distribution of expenses related to drug development.
View Article and Find Full Text PDF

The aims of the present study were to: (i) quantify accelerations and decelerations of soccer players during match-play across two consecutive seasons from the English Premier League (EPL) and Ligue 1 (L1); and (ii) compare any positional differences between the two leagues. Fifty-eight male professional soccer players were monitored during all league matches (n = 144) across seasons 2020/21 and 2021/22. The absolute number of accelerations (> +3 m/s) and decelerations (< -3 m/s) and accelerations and decelerations per minute were examined.

View Article and Find Full Text PDF

Prolonged use of antiretroviral agents has been clearly associated with nephrotoxicity, suggesting deterioration of renal function in patients receiving Highly Active Antiretroviral Therapy (HAART). The present study was designed to investigate the therapeutic efficacy of resveratrol (RV) in the treatment toxins-induced renal impairment. Twenty-four adult male Wistar rats weighing 70-90 g were divided into four groups and subjected to the following treatments: Control A (distilled water), B (HAART), C (RV-2.

View Article and Find Full Text PDF

Microbial loss significantly affects wastewater treatment efficiency. This study simulated the inoculation area of a self-developed biological doubling reactor (BDR) to evaluate the retention efficiency of seven different fillers for aerobic denitrifying bacteria. Over 90 days of continuous operation, the porous filler R3 demonstrated excellent performance, with OD values consistently exceeding 1.

View Article and Find Full Text PDF

Background: Health economic evaluations require cost data as a key input, and reimbursement policies and systems should incentivize valuable care. Subfertility is a growing global phenomenon, and Dutch per-treatment DRGs alone do not support value-based decision-making because they don't reflect patient-level variation or the impact of technologies on costs across entire patient pathways.

Methods: We present a real-world micro-costing analysis of subfertility patient pathways (n = 4.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!